Nivolumab

Red

Brand Name(s):

Indication:Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults

Rationale:1,2,3,8

Considered:Jul-21

Review Date:Jul-26

Comments:
NICE TA707

Nivolumab is recommended for treating unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults after fluoropyrimidine and platinum-based therapy. It is recommended only if the company provides nivolumab according to the commercial arrangement.

June’21